Advaxis Reports Third Quarter Ended July 31, 2022 Financial Results and Provides a Business Update

Announced completion of first dose level and enrollment initiation for second dose level in investigator-sponsored study of ADXS-504 in biochemically recurrent prostate cancer

Read more at globenewswire.com